• Home>
  • ETFs>
  • Nippon India NIFTY Pharma ETF Growth Plan
Nippon India NIFTY Pharma ETF Growth Plan share price logo

Nippon India NIFTY Pharma ETF Growth Plan Share Price (PHARMABEES)

₹19.250.57%

bell
Get free price alerts. Set up your Free investment account to get Live Prices. >

Nippon India NIFTY Pharma ETF Growth Plan Performance

  • ₹19.2
    ₹19.45
    ₹19.25
    downward going graph

    0.26%

    Downside

    Day's Volatility:1.30%

    Upside

    1.04%

    downward going graph
  • ₹11.56
    ₹20.8
    ₹19.25
    downward going graph

    39.95%

    Downside

    52 Weeks Volatility:48.00%

    Upside

    8.05%

    downward going graph
1 Month Return8.1 %
3 Month Return19.36 %
1 Year Return62.28 %
Previous Close19.36
Open19.36

Insights on Nippon India NIFTY Pharma ETF Growth Plan

Insights help you understand the recent movement of the ETF's critical parameters, giving you an overall view of the ETF.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 year, Nippon India NIFTY Pharma ETF Growth Plan has moved up by 62.28%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Motilal Oswal S&P BSE Healthcare ETF has given 65.19% return, outperforming Nippon India NIFTY Pharma ETF Growth Plan by 2.91%.

  • imgNO EFFECT

    Market Cap Breakup

    img

    Market Cap breakup for Nippon India NIFTY Pharma ETF Growth Plan is 64.49% in LARGE CAP, 26.11% in MID CAP and 9.40% in SMALL CAP with top sector being Pharmaceuticals with 100.00%

ETF Fundamentals

Expense Ratio0.21%
Avg. PE ratio44.58
Avg. PB ratio5.49
AUM₹577.79 Cr.

Companies in Nippon India NIFTY Pharma ETF Growth Plan

Companies 1D Returns
Sun Pharmaceuticals Industries LtdSun Pharmaceuticals Industries Ltd0.56
Dr Reddys Laboratories LtdDr Reddys Laboratories Ltd0.33
Cipla LtdCipla Ltd0.7
Divis Laboratories LtdDivis Laboratories Ltd0.61
Lupin LtdLupin Ltd0.39

Portfolio Breakup

  • Market Cap

  • Sector

Market Cap

Large Cap
64.49%
Mid Cap
26.11%
Small Cap
9.4%

About Nippon India NIFTY Pharma ETF Growth Plan

The Nippon India NIFTY Pharma ETF Growth Plan is an exchange-traded fund that closely tracks the NIFTY Pharma Index, comprising the top pharma stocks in India like Cipla, Divis Lab and Lupin among others. Launched in July 2021, this ETF is owned by Nippon India Mutual Fund and aims to generate returns that match the performance of the index. As the pharma sector in India is expected to grow in the long term, this ETF is ideal for investors who wish to invest in the Indian pharmaceutical industry. By investing in this ETF, investors can gain exposure to the growth potential of the Indian pharma sector and benefit from a diversified portfolio of stocks.

Owner: Nippon India Mutual Fund
Ticker: PHARMABEES
Price: ₹19.25 per unit as on 28 Feb, 2024 04:01 PM
Asset Under Management AUM: ₹577.79Cr as of today
Expense Ratio: 0.21% as of today
ExchangeNSE
E-voting on sharesClick here to vote

Frequently Asked Questions

Nippon India NIFTY Pharma ETF Growth Plan price is ₹19.25 today.

  • Today’s highest price of Nippon India NIFTY Pharma ETF Growth Plan is ₹19.45
  • Today’s lowest price of Nippon India NIFTY Pharma ETF Growth Plan is ₹19.2
Nippon India NIFTY Pharma ETF Growth PlanPrice
52 Week High
₹20.8
52 Week Low
₹11.56
Nippon India NIFTY Pharma ETF Growth PlanReturns
1 Day Returns
-0.11%
1 Month Returns
8.1%
3 Month Returns
19.36%
1 Year Returns
62.28%

Nippon India NIFTY Pharma ETF Growth Plan} price to earning (PE) ratio as on today is 44.58

You can invest via your demat account in the Nippon India NIFTY Pharma ETF Growth Plan. You can invest either through SIP mode or lumpsum mode.

Yes. Nippon India NIFTY Pharma ETF Growth Plan is available for SIP on INDmoney platform for daily, weekly or monthly SIP.

Nippon India NIFTY Pharma ETF Growth Plan's drawbacks are not related to specifically Nippon India NIFTY Pharma ETF Growth Plan. In Indian context, some of the ETFs have a drawbacks of higher tracking, lower trading volumes, etc.

Yes. Nippon India NIFTY Pharma ETF Growth Plan can used as collateral for a loan under Loan Against Securities.